A randomized, double blind, placebo controlled phase III-study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with metastastic renal cell cancer, which have progressed after VEGF receptor tyrosine kinase inhibitor therapy
Laufzeit: 01.01.2006 - 31.12.2007